ArticleAntibiotics (Basel, Switzerland)2020
Aminoglycoside 6'-
Article in Antibiotics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- Antibiotic resistance inFrontiers in microbiology · 2026Review
- Eco-Friendly Synthesis ofBioinorganic chemistry and applications · 2026Article
- Inhibiting Amikacin Resistance in Multidrug-Resistant Bacteria with Cadmium and Pyrithione.Current microbiology · 2025Review
- Prevalence of Plasmid-Mediated Fluoroquinolone Resistance Genes in Pseudomonas aeruginosa Among Patients at Aleppo University Hospital, Syria.Journal of clinical laboratory analysis · 2025Article
- Amikacin, in combination with cations, prevents growth of a carbapenem-resistant/multidrug-resistant Klebsiella pneumoniae strain isolated from a patient with COVID-19.Journal of global antimicrobial resistance · 2025Article
- Genetic Insights on Meropenem Resistance ConcerningLife (Basel, Switzerland) · 2024Article
- Structure-Activity Relationship of Pyrrolidine Pentamine Derivatives as Inhibitors of the Aminoglycoside 6'-Antibiotics (Basel, Switzerland) · 2024Article
- SilversolPharmaceutics · 2024Article
- Short reads-based characterization of pathotype diversity and drug resistance among Escherichia coli isolated from patients attending regional referral hospitals in Tanzania.BMC medical genomics · 2024Article
- Sub-lethal concentration of a colloidal nanosilver formulation (Silversol®) triggers dysregulation of iron homeostasis and nitrogen metabolism in multidrug resistant Pseudomonas aeruginosa.BMC microbiology · 2023Article
- Article
- Inhibition of Enzymatic Acetylation-Mediated Resistance to Plazomicin by Silver Ions.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Emergence ofFrontiers in microbiology · 2023Article
- Effects of levodopa on gut bacterial antibiotic resistance in Parkinson's disease rat.Frontiers in aging neuroscience · 2023Article
- Amikacin potentiator activity of zinc complexed to a pyrithione derivative with enhanced solubility.Scientific reports · 2022Article
- Molecular Epidemiology of Extensively Drug-ResistantAntibiotics (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
Abstract
Clinical resistance to amikacin and other aminoglycosides is usually due to the enzymatic acetylation of the antimicrobial molecule. A ubiquitous resistance enzyme among Gram-negatives is the aminoglycoside 6'-
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.